Nonetheless, an exciting conclusion of this review shows that among the eight anti-hypertensive agents (propranolol, hydralazine, losartan, captopril, candesartan, bosentan, minoxidil, and carvedilol) and the six anti-diabetic agents (metformin, pioglitazone, desmopressin, dapagliflozin, epalrestat, and acarbose), only epalrestat initiates its effects in breast, cervical, oral, liver, and kidney cancers by inhibiting AKR1B1/AKR1B10, the same target in diabetes and cancer [111,195]. Here, AKR1B1 is linked to cancer.